Increased tryptophan degradation in patients with bronchus carcinoma
A.B. ENGIN phd
Department of Toxicology, Faculty of Pharmacy, Gazi University, Hipodrom, Ankara
Search for more papers by this authorY. OZKAN md
Department of Biochemistry, Faculty of Pharmacy, Gazi University, Hipodrom, Ankara, Turkey
Search for more papers by this authorCorresponding Author
D. FUCHS phd
Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria
Dietmar Fuchs, Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Fritz Pregl Strasse 3, 6020 Innsbruck, Austria (e-mail: [email protected]).Search for more papers by this authorS. YARDIM-AKAYDIN md
Department of Biochemistry, Faculty of Pharmacy, Gazi University, Hipodrom, Ankara, Turkey
Search for more papers by this authorA.B. ENGIN phd
Department of Toxicology, Faculty of Pharmacy, Gazi University, Hipodrom, Ankara
Search for more papers by this authorY. OZKAN md
Department of Biochemistry, Faculty of Pharmacy, Gazi University, Hipodrom, Ankara, Turkey
Search for more papers by this authorCorresponding Author
D. FUCHS phd
Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria
Dietmar Fuchs, Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Fritz Pregl Strasse 3, 6020 Innsbruck, Austria (e-mail: [email protected]).Search for more papers by this authorS. YARDIM-AKAYDIN md
Department of Biochemistry, Faculty of Pharmacy, Gazi University, Hipodrom, Ankara, Turkey
Search for more papers by this authorAbstract
ENGIN A.B., OZKAN Y., FUCHS D. & YARDIM-AKAYDIN S. (2009) European Journal of Cancer CareIncreased tryptophan degradation in patients with bronchus carcinoma
Expression of tryptophan-degrading enzyme indoleamine (2,3)-dioxygenase in tumour tissue is proposed to represent an important tumour immunoescape mechanism. To further investigate the potential role of activated indoleamine (2,3)-dioxygenase in bronchus carcinoma, we examined serum tryptophan and kynurenine concentrations in nine patients with small cell lung cancer and in 27 patients with non-small cell lung cancer. Tryptophan metabolic changes were compared with markers of inflammation and immune activation namely C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and neopterin. Compared with controls, patients presented with lower tryptophan concentrations (P < 0.01) and with higher serum kynurenine to tryptophan ratios (P < 0.01), an index of tryptophan degradation. Also ESR and CRP and neopterin concentrations were increased in the patients (all P < 0.001), and there was a weak correlation between kynurenine to tryptophan ratio and ESR, CRP and neopterin concentrations. We conclude that in the majority of patients with non-small cell lung cancer and small cell lung cancer, enhanced tryptophan degradation can be observed. It seems to relate to an inflammatory response and may reflect activation of indoleamine (2,3)-dioxygenase at the tumour site. The capacity of the tumour to escape normal host immune defence may be influenced by tryptophan degradation. Results of this pilot study deserve further confirmation.
REFERENCES
- Arenberg D.A., Keane M.P., DiGiovine B., Kunkel S.L., Strom S.R. & Burdick M.D. (2000) Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunology and Immunotherapy 49, 63–70.
- Arpin D., Trillet-Lenoir V., Lasset C., Souquet P.J., Riou R. & Yoanidis I. (1993) Value of C-reactive protein determination in small cell lung cancer. Bulletin du Cancer 80, 1063–1068.
- Astigiano S., Morandi B., Costa R., Mastracci L., D'Agostino A. & Ratto G.B. (2005) Eosinophil granulocytes account for indoleamine 2,3-dioxygenase-mediated immune escape in human non-small cell lung cancer. Neoplasia 7, 390–396.
- Brandacher G., Perathoner A., Ladurner R., Schneeberger S., Obrist P. & Winkler C. (2006a) Prognostic value of indoleamine (2,3)-dioxygenase expression in colorectal cancer: impact on tumor-infiltrating T-cells. Clinical Cancer Research 212, 1144–1151.
- Brandacher G., Schroecksnadel K., Winkler C., Margreiter R. & Fuchs D. (2006b) Antitumoral activity of interferon-γ involved in impaired immune function in cancer patients. Current Drug Metabolism 7, 599–612.
- Burke F., Knowles R.G., East N. & Balkwill F.R. (1995) The role of indoleamine (2,3)-dioxygenase in the anti-tumour activity of human interferon-gamma in vivo. International Journal of Cancer 60, 115–122.
- Caputi M., Russo G., Esposito V., Mancini A. & Giordano A. (2005) Role of cell-cycle regulators in lung cancer. Journal of Cellular Physiology 205, 319–327.
- Denz H., Orth B., Weiss G., Herrmann R., Huber P., Wachter H. & Fuchs D. (1993) Weight loss in patients with hematological neoplasias is associated with immune system stimulation. Clinical Investigation 71, 37–41.
- Domont J., Soria J.C. & Le Chevalier T. (2005) Adjuvant chemotherapy in early-stage non-small cell lung cancer. Seminars in Oncology 32, 279–283.
- Dowlati A., Levitan N. & Remick S.C. (1999) Evaluation of interleukin-6 in bronchoalveolar lavage fluid and serum of patients with lung cancer. Journal of Laboratory and Clinical Medicine 134, 405–409.
- Friberg M., Jennings R., Alsarraj M., Dessureault S., Cantor A. & Extermann M. (2002) Indoleamine (2,3)-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. International Journal of Cancer 101, 151–155.
- Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T. & Nakakubo Y. (2006) Concurrent infiltration by CD8(+) T cells and CD4(+) T cells is a favourable prognostic factor in non-small-cell lung carcinoma. British Journal of Cancer 94, 275–280.
- Hou D.Y., Muller A.J., Sharma M.D., DuHadaway J., Banerjee T., Johnson M., Mellor A.L., Prendergast G.C. & Munn D.H. (2007) Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Research 67, 792–801.
- Huang A., Fuchs D., Widner B., Glover C., Henderson D.C. & Allen-Mersh T.G. (2002) Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. British Journal of Cancer 86, 1691–1696.
- Junker K. (2006) Current morphological diagnosis of malignant lung tumors. Pathologe 27, 90–98.
- Loeb S., Königsrainer A., Zieker D., Brücher B.L., Rammensee H.G., Opelz G. & Terness P. (2009) IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunology and Immunotherapy 58, 153–157.
- Mohamed K.H., Mobasher A.A., Yousef A.R., Salah A., El-Naggar I.Z. & Ghoneim A.H. (2001) BAL neopterin: a novel marker for cell-mediated immunity in patients with pulmonary tuberculosis and lung cancer. Chest 119, 776–780.
- Murr C., Widner B., Wirleitner B. & Fuchs D. (2002) Neopterin as a marker for immune system activation. Current Drug Metabolism 3, 175–187.
- Ortegel J.W., Staren E.D., Faber L.P., Warren W.H. & Braun D.P. (2000) Cytokine biosynthesis by tumor-infiltrating T lymphocytes from human non-small-cell lung carcinoma. Cancer Immunology and Immunotherapy 48, 627–634.
- Ozaki Y., Edelstein M.P. & Duch D.S. (1988) Induction of indoleamine (2,3)-dioxygenase: a mechanism of the antitumor activity of interferon gamma. Proceedings of the National Academy of Sciences of the United States of America 85, 1242–1246.
- Prommegger R., Widner B., Murr C., Unger A., Fuchs D. & Salzer G.M. (2000) Neopterin: a prognostic variable in operations for lung cancer. Annals of Thoracic Surgery 70, 1861–1864.
- Reibnegger G., Fuchs D., Fuith L.C., Hausen A., Werner E.R. & Werner-Felmayer G. (1991) Neopterin as a marker for activated cell-mediated immunity: application in malignant disease. Cancer Detection and Prevention 15, 483–490.
- Rossi A., Maione P., Colantuoni G., Guerriero C., Ferrara C., Del Gaizo F. & Nicolella D. (2005) Treatment of small cell lung cancer in the elderly. Oncologist 10, 399–411.
- Schroecksnadel K., Winkler C., Fuith L.C. & Fuchs D. (2005) Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Letters 223, 323–329.
- Spiro S.G. & Silvestri G.A. (2005) One hundred years of lung cancer. American Journal of Respiratory and Critical Care Medicine 172, 523–529.
- Uyttenhove C., Pilotte L., Theate I., Stroobant V., Colau D. & Parmentier N. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine (2,3)-dioxygenase. Nature Medicine 9, 1269–1274.
- Weinlich G., Murr C., Richardsen L., Winkler C. & Fuchs D. (2007) Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients. Dermatology 214, 8–14.
- Werner E.R., Bitterlich G., Fuchs D., Hausen A., Reibnegger G., Szabo G., Dierich M.P. & Wachter H. (1987) Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sciences 41, 273–280.
- Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G. & Wachter H. (1989) Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochimica et Biophysica Acta 1012, 140–147.
- Widner B., Werner E.R., Schennach H., Wachter H. & Fuchs D. (1997) Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clinical Chemistry 43, 2424–2426.
- Wirleitner B., Reider D., Ebner S., Böck G., Widner B., Jaeger M., Schennach H., Romani N. & Fuchs D. (2002) Monocyte-derived dendritic cells release neopterin. Journal of Leukocyte Biology 72, 1148–1153.
- Wood K.J. & Sawitzki B. (2005) Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends in Immunology 27, 183–187.
- Yasui H., Takai K., Yoshida R. & Hayaishi O. (1986) Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine (2,3)-dioxygenase: its possible occurrence in cancer patients. Proceedings of the National Academy of Sciences of the United States of America 83, 6622–6626.
- Yoshida R., Park S.W., Yasui H. & Takikawa O.J. (1988) Tryptophan degradation in transplanted tumor cells undergoing rejection. Immunology 141, 2819–2823.
